retatrutide triple agonist weight loss trial Retatrutide, a (GLP1, GIP, glucagon), just released phase 2 results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished retatrutide #elililly #retatrutide #weightloss #obesitycare

These pharmaceutical drugs work by directly mimicking GLP-1 at therapeutic concentrations and are approved for specific medical indications

Post-marketing reports suggest hair thinning may occur, particularly with substantial weight loss, but this likely represents telogen effluvium triggered by metabolic changes rather than direct drug toxicity

This is a conservative and practical approach

The combination of exenatide with the sodiumglucose co-transporter 2 (SGLT2) inhibitor, dapagliflozin, was investigated in the DURATION-8, phase III clinical trial which demonstrated a degree of synergy between the two agents, with improvements in short- and long-term glycaemia and weight loss exceeding either agent alone (144)

But while all fibre is good for you, there are different tolerability aspects of different fibres even at relatively small dosages: some can cause bloating, gas, and other side effects which is why you have to be careful combining fibres from different products

Realistic Weight Loss Expectations by Month Month one of semaglutide therapy typically yields 2 to 6 pounds of weight loss, with most of this coming from reduced calorie intake rather than increased metabolism